(1-Hydroxycyclopentyl)phenylacetic acid, also known as **(1-Hydroxycyclopentyl)benzeneacetic acid**, is an organic compound with the chemical formula **C13H16O3**.
**Structure:**
* It consists of a cyclopentane ring with a hydroxyl group (OH) attached to one carbon atom.
* A phenylacetic acid group (a benzene ring attached to a CH2COOH group) is attached to the other carbon atom adjacent to the hydroxyl group.
**Importance in Research:**
(1-Hydroxycyclopentyl)phenylacetic acid is not a well-studied compound, and there is limited information available on its biological or chemical properties. However, its structure suggests it could be a potential precursor or intermediate in the synthesis of various compounds, including:
* **Pharmaceuticals:** The combination of a cyclopentane ring, a hydroxyl group, and a phenylacetic acid moiety could lead to compounds with interesting pharmacological activities.
* **Materials Science:** The compound's structure might be useful in developing novel polymers or materials with specific properties.
**Research Significance:**
* **Synthesis and Characterization:** Research could focus on developing efficient methods for synthesizing (1-Hydroxycyclopentyl)phenylacetic acid and characterizing its physical and chemical properties.
* **Biological Activity:** Studies could investigate its potential biological effects, such as antimicrobial, antioxidant, or anti-inflammatory activities.
* **Chemical Reactivity:** Exploration of its chemical reactivity could lead to the development of new derivatives with interesting applications.
**Overall, (1-Hydroxycyclopentyl)phenylacetic acid is a relatively unexplored compound with potential for further research. Its unique structure and the possibility of synthesizing new derivatives could make it a valuable tool in various fields.**
(1-hydroxycyclopentyl)phenylacetic acid : (1-hydroxycyclopentyl)acetic acid in which one of the hydrogens alpha to the carboxylic acid group is substituted by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 91332 |
CHEMBL ID | 1322928 |
CHEBI ID | 59684 |
SCHEMBL ID | 628303 |
Synonym |
---|
nsc130953 |
nsc-130953 |
25209-52-3 |
MLS000079762 , |
nsc61085 |
nsc-61085 |
OPREA1_693654 |
smr000038365 |
(1-hydroxycyclopentyl)phenylacetic acid |
CHEBI:59684 , |
(1-hydroxycyclopentyl)(phenyl)acetic acid |
2-(1-hydroxycyclopentyl)-2-phenylacetic acid |
HMS2278P18 |
unii-c1gz2xu3ym |
c1gz2xu3ym , |
einecs 246-733-1 |
nsc 130953 |
nsc 61085 |
1-hydroxy-alpha-phenylcyclopentylacetic acid |
benzeneacetic acid, a-(1-hydroxycyclopentyl)- |
1-hydroxy-.alpha.-phenylcyclopentylacetic acid |
.alpha.-(1-hydroxycyclopentyl)benzeneacetic acid |
.alpha.-(1-hydroxycyclopentyl)phenylacetic acid |
cyclopentaneacetic acid, 1-hydroxy-.alpha.-phenyl- |
1-hydroxy-.alpha.-phenylcyclopentaneacetic acid |
STL321240 |
SCHEMBL628303 |
AKOS022139450 |
CHEMBL1322928 |
bdbm89560 |
2-(1-hydroxycyclopentyl)-2-phenyl-acetic acid |
2-(1-oxidanylcyclopentyl)-2-phenyl-ethanoic acid |
cid_91332 |
alpha-(1-hydroxycyclopentyl)benzeneacetic acid |
cyclopentolate hydrochloride imp. a (ep); cyclopentolate imp. a (ep); (2rs)-(1-hydroxycyclopentyl)(phenyl)acetic acid; cyclopentolate hydrochloride impurity a; cyclopentolate impurity a |
(2rs)-(1-hydroxycyclopentyl)(phenyl)acetic acid |
MHVVPVXRMHIATI-UHFFFAOYSA-N |
Q27126849 |
DTXSID901266818 |
D92968 |
CS-0336195 |
benzeneacetic acid, alpha-(1-hydroxycyclopentyl)- |
AS-77526 |
benzeneacetic acid, |a-(1-hydroxycyclopentyl)- |
Class | Description |
---|---|
tertiary alcohol | A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. |
monocarboxylic acid | An oxoacid containing a single carboxy group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 112.2020 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
corticotropin-releasing hormone receptor 2 | Homo sapiens (human) | IC50 (µMol) | 47.1000 | 0.3680 | 7.0955 | 18.0000 | AID602180 |
corticotropin releasing factor-binding protein | Homo sapiens (human) | IC50 (µMol) | 47.1000 | 0.3680 | 7.0955 | 18.0000 | AID602180 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
corticotropin-releasing hormone receptor 2 | Homo sapiens (human) | EC50 (µMol) | 53.0000 | 1.1200 | 11.5617 | 36.8000 | AID602473 |
corticotropin releasing factor-binding protein | Homo sapiens (human) | EC50 (µMol) | 53.0000 | 1.1200 | 11.5617 | 36.8000 | AID602473 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |